alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
United States Court of Appeals

FOR THE DISTRICT OF COLUMBIA CIRCUIT

____________

No. 23-5037 September Term, 2022

1:23-cv-00109-UNA

Filed On: May 23, 2023

Ronald Satish Emrit,

Appellant

v.

British Secret Service, et al.,

Appellees

ON APPEAL FROM THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF COLUMBIA

BEFORE: Wilkins and Katsas, Circuit Judges, and Sentelle, Senior Circuit

Judge

J U D G M E N T

This appeal was considered on the record from the United States District Court

for the District of Columbia and on the brief filed by appellant. See Fed. R. App. P.

34(a)(2); D.C. Cir. Rule 34(j). It is

ORDERED AND ADJUDGED that the district court’s February 10, 2023 order be

affirmed. The district court properly dismissed appellant’s case as frivolous. See 28

U.S.C. § 1915(e)(2)(B)(i); Neitzke v. Williams, 490 U.S. 319, 325 (1989) (“[A] complaint

. . . is frivolous where it lacks an arguable basis either in law or in fact.”). 

Pursuant to D.C. Circuit Rule 36, this disposition will not be published. The Clerk

is directed to withhold issuance of the mandate herein until seven days after resolution

of any timely petition for rehearing or petition for rehearing en banc. See Fed. R. App.

P. 41(b); D.C. Cir. Rule 41.

Per Curiam

FOR THE COURT:

Mark J. Langer, Clerk 

BY: /s/

Daniel J. Reidy 

Deputy Clerk
UNITED STATES COURT OF APPEALS 

FOR THE TENTH CIRCUIT 

_________________________________ 

UNITED STATES OF AMERICA, 

 Plaintiff - Appellee, 

v. 

MANUEL ESPINOZA-TALAMANTES, 

 Defendant - Appellant. 

No. 18-2123 

(D.C. No. 2:18-CR-01029-WJ-1) 

(D. N.M.) 

_________________________________ 

ORDER AND JUDGMENT*

_________________________________ 

Before TYMKOVICH, Chief Judge, HOLMES and McHUGH, Circuit Judges. 

_________________________________ 

Following his acceptance of a plea agreement that included a waiver of his 

right to appeal, Manuel Espinoza-Talamantes pleaded guilty to re-entry of a removed 

alien in violation of 8 U.S.C. § 1326(a) and (b). He was sentenced to 42 months’ 

imprisonment. Despite the waiver, he appealed. The government has moved to 

enforce the appeal waiver. See United States v. Hahn, 359 F.3d 1315, 1328 

(10th Cir. 2004) (en banc) (per curiam). 

In evaluating a motion to enforce a waiver, we consider: “(1) whether the 

disputed appeal falls within the scope of the waiver of appellate rights; (2) whether 

 * This order and judgment is not binding precedent, except under the doctrines 

of law of the case, res judicata, and collateral estoppel. It may be cited, however, for 

its persuasive value consistent with Fed. R. App. P. 32.1 and 10th Cir. R. 32.1. 

FILED 

United States Court of Appeals 

Tenth Circuit 

November 9, 2018

Elisabeth A. Shumaker 

Clerk of Court
2 

the defendant knowingly and voluntarily waived his appellate rights; and (3) whether 

enforcing the waiver would result in a miscarriage of justice.” Id. at 1325. 

Espinoza-Talamantes’ counsel has filed a response in which he says that he “does not 

have a good faith legal or factual basis to contest the government’s [m]otion.” 

Resp. at 1. 

Our independent review confirms that the proposed issue for appeal (identified 

as an appeal of his sentence in Espinoza-Talamantes’ Docketing Statement) falls 

within the scope of his waiver. The plea agreement clearly sets forth the waiver and 

states that it was knowing and voluntary, and the district court discussed the waiver 

and voluntariness at the plea hearing. There is no contradictory evidence indicating 

that Espinoza-Talamantes did not knowingly and voluntarily accept the waiver. 

Finally, there is no indication that enforcing the waiver would result in a miscarriage 

of justice as defined in Hahn, 359 F.3d at 1327. 

The motion to enforce is granted and the appeal is dismissed. 

Entered for the Court 

Per Curiam
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3035 Amikacin test system. ( a ) *Identification.* An amikacin test system is a device intended to measure amikacin, an aminoglycoside antibiotic drug, in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of amikacin overdose and in monitoring levels of amikacin to ensure appropriate therapy.
( b ) *Classification.* Class II.
EXHIBIT 99.3

REPORT OF INDEPENDENT ACCOUNTANTS

To the Partners of Hanford L.P.:

In our  opinion,  the  balance  sheets  and the  related  statements  of income,
partners'  equity,  and cash flows of Hanford  L.P.  (not  presented  separately
herein)  present fairly,  in all material  respects,  the financial  position at
December 31, 1998 and 1999, and the results of its operations and its cash flows
for the three years in the period ended  December 31, 1999, in  conformity  with
accounting  principles  generally accepted in the United States. These financial
statements  are  the  responsibility  of  the  Partnership's   management;   our
responsibility  is to express an opinion on these financial  statements based on
our audits.  We conducted  our audits of these  statements  in  accordance  with
auditing standards  generally accepted in the United States,  which require that
we plan and perform the audit to obtain  reasonable  assurance about whether the
financial  statements  are free of  material  misstatement.  An  audit  includes
examining,  on a test basis,  evidence supporting the amounts and disclosures in
the  financial   statements,   assessing  the  accounting  principles  used  and
significant  estimates made by management,  and evaluating the overall financial
statement  presentation.  We believe that our audits provide a reasonable  basis
for the opinion expressed above.

San Fransisco, California                         /s/ PricewaterhouseCoopers LLP
March 3, 2000
To: Joel Bredow CEO April 25, 2015

From: Drone Services Hawaii Subject: Authorization Letter This letter is to authorize George K. Purdy, of Drone Services Hawaii, 98 - 1827A Kaahumanu St., Aiea, Hi 96701, Cell phone (808)559 - 0175, Phone (808)225 - 2968, Fax (808)445 - 1954, online access for IR DI STRO INC section 333 exemption document Process. Joel Bredow CEO
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1730 Free tyrosine test system. ( a ) *Identification.* A free tyrosine test system is a device intended to measure free tyrosine (an amono acid) in serum and urine. Measurements obtained by this device are used in the diagnosis and treatment of diseases such as congenital tyrosinemia (a disease that can cause liver/kidney disorders) and as an adjunct to the measurement of phenylalanine in detecting congenital phenylketonuria (a disease that can cause brain damage).
( b ) *Classification.* Class I.
§ 582.6511 Monoisopropyl citrate. ( a ) *Product.* Monoisopropyl citrate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Transportation

###### Office of the Secretary

The following Agreements were filed with the Department of Transportation under the Sections 412 and 414 of the Federal Aviation Act, as amended (49 U.S.C. 1382 and 1384) and procedures governing proceedings to enforce these provisions. Answers may be filed within 21 days after the filing of the application.

*Docket Number:*                     DOT-OST-2010-0031.                

*Date Filed:*                     February 9, 2010.                

*Parties:*                     Members of the International Air Transport Association.                

*Subject:*                     Mail Vote 621.                

Special Passenger Amending Resolution 010n,  from Hong Kong SAR to India,  (Memo 1355).

Intended effective date: 22 February 2010.

*Docket Number:*                     DOT-OST-2010-0032.                

*Date Filed:*                     February 9, 2010.                

*Parties:*                     Members of the International Air Transport Association.                

*Subject:*                     Mail Vote 619.                 

TC3 Special Passenger Amending Resolution 010m  between Korea (Rep. of) and  China excluding Hong Kong SAR and Macao SAR,  (Memo 1354).

Intended effective date: 15 February 2010.

*Docket Number:*                     DOT-OST-2010-0033.                

*Date Filed:*                     February 12, 2010.                

*Parties:*                     Members of the International Air Transport Association.                

*Subject:*                     Mail Vote 622.                

TC3 Within South East Asia,  Special Passenger Amending Resolution 010o  between Viet Nam and Myanmar  (Memo 1356). 

Intended effective date: 22 February 2010.

Renee V. Wright,

Program Manager, Docket Operations, Federal Register Liaison.

[FR Doc. 2010-4674 Filed 3-4-10; 8:45 am]

BILLING CODE 4910-9X-P
```

[Federal Register Volume 80, Number 205 (Friday, October 23, 2015)]
[Rules and Regulations]
[Page 64312]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C1-2015-25606]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2012-0913; Directorate Identifier 2012-NE-23-AD; 
Amendment 39-18261; AD 2015-18-03]
RIN 2120-AA64

Airworthiness Directives; Honeywell International Inc. Turboprop 
Engines (Type Certificate Previously Held by AlliedSignal Inc., Garrett 
Engine Division; Garrett Turbine Engine Company; and AiResearch 
Manufacturing Company of Arizona)

Correction

    In rule document 2015-25606, appearing on pages 61091 through 61093 
in the issue of Friday, October 9, 2015, make the following correction:
    On page 61093, at the top of the page, the image heading ``Figure 2 
to Paragraph (e)--Airplane Operating Procedures'' should read ``Figure 
1 to Paragraph (e)--Airplane Operating Procedures''.

[FR Doc. C1-2015-25606 Filed 10-22-15; 8:45 am]
 BILLING CODE 1505-01-D
```
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.1820 Dental x-ray exposure alignment device. ( a ) *Identification.* A dental x-ray exposure alignment device is a device intended to position x-ray film and to align the examination site with the x-ray beam.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 59 FR 63008, Dec. 7, 1994; 66 FR 38797, July 25, 2001]
§ 573.225 1,3-Butylene glycol. The food additive 1,3-butylene glycol (1,3-butanediol) may be safely used in accordance with the following prescribed conditions: ( a ) It complies with the specifications in § 173.220(a) of this chapter.
( b ) It is intended for use in swine feed as a source of energy.
( c ) It is to be thoroughly mixed into feed at levels not to exceed 9 percent of the dry matter of the total ration.
( d ) 1,3-Butylene glycol should be mixed in feed with equipment adapted for the addition of liquids, and the feed should be mixed not less than 5 minutes after its addition.
[53 FR 40061, Oct. 13, 1988]
# C_2016270EN.01006702.xml

| 25.7.2016 | EN | Official Journal of the European Union | C 270/67 |
| --- | --- | --- | --- |

25.7.2016

EN

Official Journal of the European Union

C 270/67

---

Order of the General Court of 1 June 2016 — Laboratoire Nuxe v EUIPO — NYX, Los Angeles (NYX)

(Case T-537/14) (1)

1

(2016/C 270/73)

Language of the case: English

The President of the Seventh Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 329, 22.9.2014.

1

---
I 

118TH CONGRESS 

2D SESSION H. R. 7675 

To extend the authorization of appropriations for PFAS research and 

development by the Environmental Protection Agency. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 13, 2024 

Mr. PAPPAS (for himself and Mr. POSEY) introduced the following bill; which 

was referred to the Committee on Energy and Commerce, and in addition 

to the Committees on Science, Space, and Technology, and Transportation and Infrastructure, for a period to be subsequently determined by 

the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To extend the authorization of appropriations for PFAS research and development by the Environmental Protection 

Agency. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘PFAS Research and 

5 Development Reauthorization Act of 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7675 IH

1 SEC. 2. AUTHORIZATION. 

2 Section 7362(b) of the National Defense Authoriza3 tion Act for Fiscal Year 2020 (15 U.S.C. 8962(b)) is 

4 amended by striking ‘‘2024’’ and inserting ‘‘2029’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
# C_2014351EN.01000301.xml

| 6.10.2014 | EN | Official Journal of the European Union | C 351/3 |
| --- | --- | --- | --- |

6.10.2014

EN

Official Journal of the European Union

C 351/3

---

Request for a preliminary ruling from the Krajský súd v Prešove (Slovakia) lodged on 4 July 2014 — CD Consulting s.r.o. v Anna Pančurová and Others

(Case C-328/14)

2014/C 351/03

Language of the case: Slovak

Referring court

Referring court

Krajský súd v Prešove

Parties to the main proceedings

Parties to the main proceedings

Applicant: CD Consulting s.r.o.

Applicant:

Defendants: Anna Pančurová and Others

Defendants:

Question referred

Question referred

Must Article 6(1) of Council Directive 93/13/EEC (1) of 5 April 1993 on unfair terms in consumer contracts and Article 4 of Council Directive 87/102/EEC (2) of 22 December 1986 for the approximation of the laws, regulations and administrative provisions of the Member States concerning consumer credit be interpreted as precluding legislation of a Member State, such as the legislation at issue in the main proceedings, which in principle does not allow the national court deciding on rights under an endorsed bill of exchange at any stage of the proceedings to examine of its own motion the agreement and the basis of the legal relationship and the possible unfair nature of a contractual term and any breach of the law regulating the consequences of the failure to state the APR in the consumer credit agreement from which the bill of exchange arose?

1

2

---

(1)  OJ 1993 L 95, p. 29.

1

(2)  OJ 1993 L 42, p. 48.

2

---
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S CONSOLIDATED FINANCIAL STATEMENTS OF INCOME AND CONSOLIDATED BALANCE
SHEETS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                             APR-01-2000
<PERIOD-END>                               JUL-01-2000
<CASH>                                          21,167
<SECURITIES>                                     3,145
<RECEIVABLES>                                   89,079
<ALLOWANCES>                                     3,284
<INVENTORY>                                    145,436
<CURRENT-ASSETS>                               270,755
<PP&E>                                          22,365
<DEPRECIATION>                                  10,673
<TOTAL-ASSETS>                                 293,792
<CURRENT-LIABILITIES>                          197,992
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            15
<OTHER-SE>                                      95,785
<TOTAL-LIABILITY-AND-EQUITY>                   293,792
<SALES>                                        148,189
<TOTAL-REVENUES>                               148,189
<CGS>                                          128,628
<TOTAL-COSTS>                                  128,628
<OTHER-EXPENSES>                                15,041
<LOSS-PROVISION>                                   233
<INTEREST-EXPENSE>                                  63
<INCOME-PRETAX>                                  4,920
<INCOME-TAX>                                     1,929
<INCOME-CONTINUING>                              2,986
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,986
<EPS-BASIC>                                        .23
<EPS-DILUTED>                                      .23


</TABLE>
## Docket No. FAA-2012-0270
§ 606.145 Control of bacterial contamination of platelets. ( a ) Blood collection establishments and transfusion services must assure that the risk of bacterial contamination of platelets is adequately controlled using FDA approved or cleared devices or other adequate and appropriate methods found acceptable for this purpose by FDA.
( b ) In the event that a blood collection establishment identifies platelets as bacterially contaminated, that establishment must not release for transfusion the product or any other component prepared from the same collection, and must take appropriate steps to identify the organism.
( c ) In the event that a transfusion service identifies platelets as bacterially contaminated, the transfusion service must not release the product and must notify the blood collection establishment that provided the platelets. The transfusion service must take appropriate steps to identify the organism; these steps may include contracting with the collection establishment or a laboratory to identify the organism. The transfusion service must further notify the blood collection establishment either by providing information about the species of the contaminating organism when the transfusion service has been able to identify it, or by advising the blood collection establishment when the transfusion service has determined that the species cannot be identified.
( d ) In the event that a contaminating organism is identified under paragraph (b) or (c) of this section, the collection establishment's responsible physician, as defined in § 630.3(i) of this chapter, must determine whether the contaminating organism is likely to be associated with a bacterial infection that is endogenous to the bloodstream of the donor, in accordance with a standard operating procedure developed under § 606.100(b)(22). This determination may not be further delegated.
[80 FR 29895, May 22, 2015]
______________________________________________________________ Page is not included in this copy. Pages 13 through 14 are not included in this copy.

_________________________________________________________________ The material not included contains the following type of information:

__ __ Identity of product inert ingredients.

__ __ Identity of product impurities.

__ __ Description of the product manufacturing process.

__ __ Description of quality control procedures.

__ __ Identity of the source of product ingredients. _____ Sales or other commercial/financial information. _____ A draft product label. _____ The product confidential statement of formula. _____ Information about a pending registration action.

__ __ FIFRA registration data.

__ __ The document is a duplicate of page(s) _ . _____ The document is not responsive to the request.

__ __ Internal deliberative information. _____ Attorney-Client work product.

__ X __ Claimed Confidential by submitter upon submission to the Agency.______________________________________________________________ Page is not included in this copy. Pages 72 through 76 are not included in this copy.

_________________________________________________________________ The material not included contains the following type of information: _____ Identity of product inert ingredients.

__ __ Identity of product impurities.

__ __ Description of the product manufacturing process.

__ __ Description of quality control procedures.

__ __ Identity of the source of product ingredients. _____ Sales or other commercial/financial information. _____ A draft product label.

__ X __ The product confidential statement of formula. _____ Information about a pending registration action.

__ __ FIFRA registration data.

__ __ The document is a duplicate of page(s) _ . _____ The document is not responsive to the request.

__ __ Internal deliberative information.

__ __ Privileged attorney-client communication.

__ __ Claimed Confidential by submitter upon submission to the Agency.